648439-19-4Relevant academic research and scientific papers
Method for preparation of aromatic alcohol by photocatalysis of aromatic aldehyde conversion
-
Paragraph 0061-0063, (2020/04/17)
The invention relates to a method for preparation of aromatic alcohol by photocatalysis of aromatic aldehyde conversion. By means of a photocatalyst, under the conditions of illumination and inert gas, fatty alcohol is adopted as a proton donor for reduction reaction on aromatic aldehyde to obtain corresponding aromatic alcohol. Fatty alcohol is used as the proton donor, and light energy is used as the energy source to promote high-conversion-rate and high-selectivity synthesis of a series of aromatic alcohol compounds from aromatic aldehyde, the method has universal applicability, and is expected to realize industrial production; and the reaction process is green and environment-friendly, low in cost, easy to operate, short in reaction period, high in conversion rate and good in selectivity.
Insight into the complete substrate-binding pocket of ThiT by chemical and genetic mutations
Swier,Monjas,Ree?ing,Oudshoorn,Aisyah,Primke,Bakker,Van Olst,Ritschel,Faustino,Marrink,Hirsch,Slotboom
supporting information, p. 1121 - 1130 (2017/07/12)
Energy-coupling factor (ECF) transporters are involved in the uptake of micronutrients in bacteria. The transporters capture the substrate by high-affinity binding proteins, the so-called S-components. Here, we present the analysis of two regions of the s
PYRIDONE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
-
Page/Page column 80, (2010/04/03)
The present invention relates to 2-pyridone derivatives of Formula (I) or (IV) as herein described, compositions containing such compounds, synthetic processes for making such compounds, and therapeutic methods that include the administration of such comp
DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS
-
, (2009/10/09)
The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
